Hypophosphatasia (HPP) Cell Models for Research

Hypophosphatasia (HPP) is a rare inherited metabolic disorder caused by mutations in the ALPL gene, leading to deficiency of tissue-nonspecific alkaline phosphatase (TNAP). The global incidence is estimated at 1 in 100,000 for severe forms, but milder forms may be more common. According to the National Institutes of Health (NIH), HPP affects both children and adults, with symptoms ranging from rickets and bone deformities in infancy to dental issues, muscle weakness, and fractures in adulthood. The clinical impact is significant, with severe perinatal and infantile forms being life-threatening if untreated. The 5-year survival for severe infantile HPP is poor without enzyme replacement therapy, but with treatment (e.g., asfotase alfa), outcomes improve. The disease burden includes chronic pain, mobility issues, and reduced quality of life. Research is crucial to understand the molecular mechanisms and develop targeted therapies.

HPP is an ideal model for studying bone metabolism, mineralization, and enzyme replacement strategies. The disease is monogenic, making it amenable to gene editing. Public datasets, such as the ALPL gene variant database (ClinVar), provide extensive mutation information. Open questions include the genotype-phenotype correlation, the role of TNAP in non-skeletal tissues, and the development of small-molecule chaperones or gene therapies. Gene-edited cell models allow researchers to study specific ALPL mutations in a controlled environment, facilitating drug screening and functional studies.

The primary defect in HPP is the deficiency of TNAP, an enzyme that hydrolyzes inorganic pyrophosphate (PPi) to inorganic phosphate (Pi). This leads to extracellular accumulation of PPi, which inhibits hydroxyapatite crystal formation and bone mineralization. Key pathways include:

• • Mineralization pathway: TNAP cleaves PPi, promoting bone mineralization. Deficiency leads to rickets/osteomalacia.
• • Pyridoxal 5'-phosphate (PLP) metabolism: TNAP dephosphorylates PLP to pyridoxal, which is essential for neurotransmitter synthesis. Deficiency causes seizures in severe forms.
• • Inflammation and phosphate metabolism: TNAP may modulate inflammation and phosphate homeostasis, affecting multiple organs.

Data from ClinVar and the ALPL gene mutation database (http://www.sesep.uvsq.fr/03hypomutations.php).

TNAP deficiency disrupts several signaling networks:

• • Bone morphogenetic protein (BMP) signaling: TNAP may regulate BMP2/4 activity by dephosphorylating substrates. Deficiency alters osteoblast differentiation.
• • Wnt signaling: TNAP interacts with Wnt ligands, affecting β-catenin pathway and bone formation.
• • Purine signaling: TNAP modulates extracellular ATP/adenosine levels, influencing P2 receptors and inflammation.
• • Pyridoxal phosphate metabolism: Affects neurotransmitter synthesis, impacting neurological function.

Organoids derived from patient iPSCs can recapitulate bone mineralization defects and are useful for studying HPP in a 3D context.

• • Alpl knockout mice: Complete loss of TNAP leads to severe HPP phenotype, including seizures and skeletal defects.
• • Alpl hypomorphic mice: Partial loss of activity models mild forms.
• • Patient-derived xenograft (PDX) models: Not commonly used for HPP due to metabolic nature, but bone tissue from patients can be implanted.
• • Induced models: CRISPR-engineered mice with specific ALPL mutations (e.g., p.Asp361Val) are available.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with specific ALPL mutations. For example:

• • ALPL knockout cell lines: Complete loss of TNAP activity, mimicking severe HPP.
• • ALPL knock-in cell lines: Introduction of patient-specific point mutations (e.g., p.Glu174Lys) to study genotype-phenotype correlations.

These models are sequence-verified and can be used for functional assays, drug screening, and mechanistic studies. Commercially available, validated models accelerate research by providing consistent and reproducible results. Researchers can also request custom gene-edited cell lines to match their specific needs.

Knockout and knock-in lines are used to validate the role of ALPL in mineralization and other pathways. For example, ALPL knockout osteoblasts show reduced mineralization, confirming the enzyme's role. Knock-in lines with specific mutations can be used to assess the impact of variants on protein function and response to therapies.

Isogenic pairs (wild-type vs. mutant) are used to screen for compounds that increase TNAP activity or bypass the defect. For instance, small molecules that act as chaperones or upregulate ALPL expression can be tested. Resistance mechanisms to enzyme replacement therapy can be studied by exposing cells to asfotase alfa and selecting for resistant clones.

CRISPR-based synthetic lethality screens can identify genes that, when silenced, are lethal in ALPL-deficient cells but not in wild-type cells. This can reveal potential therapeutic targets. Additionally, gene-edited cells can be used to discover biomarkers for disease severity or treatment response.